The FDA gave Abbott Laboratories (ABT) the green light on Monday to market its Volt PFA System for treating patients with atrial fibrillation, the most common type of irregular heart rhythm affecting millions of Americans.

Atrial fibrillation happens when the heart's upper chambers start quivering rapidly and chaotically instead of beating in a coordinated rhythm. Think of it as your heart's electrical system going haywire. The result? A fast, irregular pulse, palpitations, shortness of breath, fatigue, and a significantly higher risk of blood clots, stroke, and heart failure because blood isn't flowing the way it should.

Abbott plans to launch commercial procedures in the United States soon and continue expanding availability across European Union sites following CE Mark approval earlier this year.

The Scale of the Problem

Here's the sobering reality: approximately 12 million Americans over 65 currently live with AFib, and that number is expected to double over the next two decades. As the population ages, effective treatment options become increasingly critical.

The FDA based its approval on results from Abbott's VOLT-AF IDE study, which enrolled 392 patients. The data demonstrated clinically meaningful performance for both paroxysmal atrial fibrillation (PAF), where episodes come and go, and persistent AFib (PersAF), where episodes last longer than seven days.

What Makes Volt Different

Abbott designed the Volt PFA System with physician workflow in mind. It integrates with the company's EnSite X EP System to provide accurate 3D cardiac mapping while requiring fewer catheter exchanges during ablation procedures.

Most competitive PFA systems on the market require multiple therapy applications with catheters positioned in various locations. The Volt system was engineered to address these limitations by delivering precise, targeted energy that helps create durable lesions with fewer pulses. That translates to more effective first-time procedures, reducing the need for repeat ablations and minimizing complication risks.

The Patient Experience

One significant advantage: patients undergoing the minimally invasive ablation with the Volt PFA Catheter can be placed under conscious sedation rather than general anesthesia. For patients where anesthesia poses a barrier, this opens up treatment options that might otherwise be unavailable.

The system also reduces radiation exposure from fluoroscopy and limits hemolysis, the breakdown of red blood cells during the procedure.

Stock Movement: Abbott Laboratories shares traded up 0.51% at $126.08 at the time of publication on Monday.